AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9597213
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg ephedrine i.m.
Trial: 30746344
Drug: Eicosapentaenoic Acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic Acid (EPA) 2 g/day
Trial: 26197768
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or radiotherapy alone
Trial: 22222177
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (sham treatment with disconnected ultrasound equipment)
Trial: 21439960
Drug: High-dose pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pegylated IFN-α2a (360 μg once per week or 180 μg twice per week) with ribavirin (1.0-1.2 or 1.2-1.6 g/d) for up to 72 weeks
Trial: 21439960
Drug: High-dose pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pegylated IFN-α with ribavirin
Trial: 18505948
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (intention-to-treat analysis)
Trial: 16927381
Drug: Exposure-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based behavioral treatment
Trial: 16927381
Drug: Non-exposure-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exposure-based behavioral treatment
Trial: 16927381
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (core treatment)
Trial: 8808422
Drug: Ranitidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 200 mg/day by continuous infusion
Trial: 8808422
Drug: Ranitidine 400
RxNorm normalized name: ranitidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 400 mg/day by continuous infusion
Trial: 30268713
Drug: Age-appropriate preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-appropriate preparation for children undergoing radiotherapy
Trial: 26621361
Drug: IFNgamma (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNgamma (human recombinant interferon 1 b gamma, trade name IMUKIN) administered in 3 subcutaneous escalating doses (100, 150 and 200 mug) over 4 weeks
Trial: 25350474
Drug: Opioid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid treatment with an average of 144.5 ± 127.8 mg/d of MED, including 57.1% long-acting and 91.4% short-acting opioids.
Trial: 25350474
Drug: Positive urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive urine drug tests (UDT) for illicit drugs or unprescribed medications (N = 15).
Trial: 18936571
Drug: Postoperative glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative glucose levels between 110 to 200 mg/dL
Trial: 18936571
Drug: Postoperative glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative glucose levels greater than 200 mg/dL
Trial: 1936476
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Glibenclamide
Trial: 1936476
Drug: Metformin (long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (long term therapy)
Trial: 27503042
Drug: Hydroxyzine 50
RxNorm normalized name: hydroxyzine hydrochloride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 50 mg (active control)
Trial: 19699071
Drug: Nutraceutical combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical combination (NC) - 500 mg berberine, 200 mg red yeast rice, 10 mg policosanols
Trial: 7794069
Drug: 0.2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/day recombinant human growth hormone (rhGH)
Trial: 2218422
Drug: Pivmecillinam 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 700 mg t.i.d.
Trial: 28810477
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy self-help intervention (self-help booklet and telephone support)
Trial: 23783081
Drug: Quinvaxem(®) vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinvaxem(®) vaccine administered at 6, 10, and 14 weeks of age
Trial: 23783081
Drug: Quinvaxem(®) vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinvaxem(®) vaccine
Trial: 19057416
Drug: Herbal formula
RxNorm normalized name: Osteo Bi-Flex Joint Health Herbal Formula With Turmeric Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal formula (equivalent to 3,150 mg dry herb)
Trial: 14615473
Drug: 10% oral
RxNorm normalized name: Xylocaine 10% Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% oral solution of levetiracetam (750 mg)
Trial: 14615473
Drug: 750-mg tablet
RxNorm normalized name: levetiracetam 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750-mg tablet of levetiracetam
Trial: 9589819
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1%-salicylic acid 5% ointment
Trial: 30773266
Drug: Liraglutide (aiming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (aiming at 3 mg daily for 12 weeks)
Trial: 28103158
Drug: sumatriptan iontophoretic
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan iontophoretic transdermal system (TDS)
Trial: 28103158
Drug: 5‐HT1F receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT1F receptor agonist lasmiditan
Trial: 28103158
Drug: 5‐HT2B and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT2B and 5‐HT7 receptor antagonism
Trial: 25371534
Drug: HZ/su vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su vaccine (50 µg varicella-zoster virus glycoprotein E [gE] combined with AS01B adjuvant)
Trial: 23547788
Drug: E. guineensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. guineensis leaf extract 500 mg
Trial: 23547788
Drug: E. guineensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. guineensis leaf extract 1000 mg
Trial: 23547788
Drug: F. deltoidea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F. deltoidea leaf extract 1000 mg
Trial: 20714991
Drug: Oral lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lutein supplementation
Trial: 20714991
Drug: Fixed lutein/omega-3-fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed lutein/omega-3-fatty acid combination
Trial: 20073226
Drug: Citrate-mosapride tablet
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate-mosapride tablet
Trial: 11691566
Drug: Cefaclor (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (25 mg/kg/bid) for 5 days
Trial: 11691566
Drug: Cefaclor (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (25 mg/kg/bid) for 10 days
Trial: 9143642
Drug: Yohimbine 20
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 20 mg once a day
Trial: 9143642
Drug: Yohimbine 5
RxNorm normalized name: yohimbine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 5 mg three times a day
Trial: 9143642
Drug: Yohimbine 10
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 10 mg three times a day
Trial: 23460709
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy (arm A)
Trial: 23460709
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy and erlotinib 150 mg per day (arm B)
Trial: 17979577
Drug: Moderate to
RxNorm normalized name: GenTeal Moderate to Severe Ophthalmic Gel Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate to severe ADHD treatment
Trial: 15494637
Drug: Pelvic radiotherapy
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiotherapy concurrently with weekly gemcitabine at 300 mg/m2
Trial: 11710635
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 i.v. bolus) followed 24 h later by paclitaxel (200 mg/m2 i.v. over 3 h)
Trial: 11710635
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 i.v. bolus) followed 30 min later by paclitaxel (200 mg/m2 i.v. over 3 h)
Trial: 8045206
Drug: First group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First group intestinal preparation
Trial: 8045206
Drug: Second group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second group intestinal preparation
Trial: 8045206
Drug: Third group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third group intestinal preparation
Trial: 27317414
Drug: Idarucizumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (1, 2.5 and 5 g or 2 × 2.5 g 1 h apart)
Trial: 27317414
Drug: Idarucizumab (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (doses ≥2.5 g)
Trial: 24431895
Drug: LdT (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LdT (600 mg/d orally) + ADV (10 mg/d orally)
Trial: 24431895
Drug: LAM (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM (100 mg/d orally) + ADV (10 mg/d orally)
Trial: 18450930
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for late-life depression (structured conditions for up to 12 weeks)
Trial: 14679117
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 (arm A)
Trial: 14679117
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 (arm B)
Trial: 9134632
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants for up to six months (discontinued after the first event)
Trial: 27986370
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ethyl chloride spray)
Trial: 23881346
Drug: BIB® (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIB® (6 months) followed by diet therapy (7 months)
Trial: 21976264
Drug: Client-oriented Occupational
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-oriented Occupational Therapy methods
Trial: 9751013
Drug: Engerix B
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix B (1 ml, 20 micrograms)
Trial: 9751013
Drug: Hepavax (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepavax (1 ml, 20 micrograms)
Trial: 9751013
Drug: Gen Hevac
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gen Hevac B (combined S and PreS subunit vaccine, 1 ml, 20 micrograms)
Trial: 9751013
Drug: Standard isolated
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard isolated S-antigen-containing vaccines (Engerix B or Hepavax)
Trial: 3411179
Drug: Progesterone in
RxNorm normalized name: Progesterone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone in oil 25 mg intramuscularly daily from day +4 to day +18
Trial: 25017114
Drug: Iced-slush ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iced-slush ingestion (SLUSH), 7 g·kg(‐1) body weight
Trial: 8556970
Drug: Carbamazepine 400
RxNorm normalized name: carbamazepine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 400 mg daily
Trial: 1977949
Drug: Aerosolized beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized beta 2‐agonists only
Trial: 1977949
Drug: Combined aerosolized
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined aerosolized beta 2‐agonists with intravenous AMP
Trial: 1977949
Drug: Intravenous AMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous AMP
Trial: 1977949
Drug: Aerosolized beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized beta 2‐agonists
Trial: 343788
Drug: Metamizole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizole (2.5 mg)
Trial: 31370668
Drug: 3‐mL intra‐articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mL intra‐articular injection of atelocollagen (BioCollagen group)
Trial: 23305083
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (20 mg rabeprazole and 1 g amoxicillin for the first week, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole for the second week)
Trial: 23305083
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (20 mg rabeprazole, 1 g amoxicillin, 500 mg clarithromycin, and 500 mg metronidazole for 2 weeks)
Trial: 19581544
Drug: Infants born
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants born to mothers shorter than 145 cm weighing 3300 g
Trial: 9156377
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium (500 mg every 12 hours)
Trial: 3534201
Drug: Thiopental treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental treatment
Trial: 23286558
Drug: Metacognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive therapy (MCT), 11 to 13 sessions
Trial: 22100355
Drug: Multidisciplinary cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary cognitive behavioral treatment program
Trial: 2148632
Drug: MPA treatment
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA treatment with mild exercise
Trial: 2148632
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with mild exercise
Trial: 2148632
Drug: MPA treatment
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA treatment
Trial: 31834099
Drug: LOW (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW (150 mg·kg body mass tyrosine)
Trial: 31834099
Drug: MED (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MED (300 mg·kg body mass tyrosine)
Trial: 31834099
Drug: HIGH (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH (400 mg·kg body mass tyrosine)
Trial: 31834099
Drug: PLA (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA (0 mg tyrosine)
Trial: 28746178
Drug: High CMV
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CMV viral load (>2.52 log copies/mL)
Trial: 28746178
Drug: Low CMV
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low CMV viral load (≤2.52 log copies/mL)
Trial: 23139359
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d atorvastatin
Trial: 16154544
Drug: D-alanine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-alanine (100 mg/kg/day)
Trial: 14633532
Drug: Triple preincisional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple preincisional analgesic therapy (rofecoxib 50 mg PO, 0.25% bupivacaine/0.5% lidocaine field block, ketamine 0.2 mg/kg IV)
Trial: 1347763
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg xamoterol twice daily
Trial: 1347763
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg xamoterol twice daily
Trial: 1347763
Drug: Xamoterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (100 mg and 200 mg)
Trial: 3896701
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen administration
Trial: 30208475
Drug: aP vaccine
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aP vaccine plus HBV (n = 221)
Trial: 22370444
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g WBE/d
Trial: 22370444
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g WBE/d
Trial: 22370444
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g WBE/d (placebo)
Trial: 18540008
Drug: Transfers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfers of only embryos from rHuPH20 treatment
Trial: 18540008
Drug: Transfers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfers of only embryos from bovine hyaluronidase treatment
Trial: 15935238
Drug: Continuing mood
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing mood stabilizer therapy
Trial: 8740607
Drug: Amitriptyline (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (dose escalated from 25 mg to 100 mg per day over 4 weeks)
Trial: 7046784
Drug: Co-trimoxazole by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole by intramuscular injection immediately before operation
Trial: 31177635
Drug: Theatre Improvisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theatre Improvisation Training to Promote Social Cognition (TIPS) - 18 weekly 2-hour group sessions led by a theatre director and actor-assistant.
Trial: 25050468
Drug: CMV pp65
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV pp65 messenger RNA‐loaded autologous monocyte‐derived dendritic cells (DC) administered intradermally at a weekly interval for 4 weeks
Trial: 19236376
Drug: Sequential deferiprone-deferoxamine
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sequential deferiprone-deferoxamine (DFO-DFP)
Trial: 17599426
Drug: Simvastatin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (titrated to 40 mg/day if necessary) plus placebo
Trial: 17599426
Drug: Simvastatin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (titrated to 40 mg/day if necessary) plus active fenofibrate 160 mg/day (or 54 mg/day if eGFR 30 to <50 mL/min per 1.73 m2)
Trial: 15533894
Drug: Retinyl palmitate
RxNorm normalized name: Retinyl palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl palmitate supplementation (25,000, 50,000, or 75,000 IU daily)
Trial: 9802965
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg nebulized glyceryl trinitrate (GTN)
Trial: 2681580
Drug: Intravenous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terbutaline (IURT)
Trial: 30742386
Drug: Combined effect
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined effect of magnetolaser therapy (MLT) and red light (10 procedures per course)
Trial: 30742386
Drug: Basic therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapeutic complex (medicamentous therapy, prostate massage, diet therapy, therapeutic gymnastics)
Trial: 26279411
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (GTN) 0.4 mg/h
Trial: 24912462
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) combined with venlafaxine XR, 12 sessions
Trial: 24912462
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) combined with venlafaxine XR
Trial: 24912462
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (European Americans receiving combined treatment)
Trial: 9140633
Drug: New atypical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New atypical antipsychotic
Trial: 3300133
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg orally 1 hour before abortion and again 4 and 8 hours after